Strategies and challenges for the next generation of therapeutic antibodies

被引：642

作者：

Beck, Alain ^{[1
]}

Wurch, Thierry ^{[1
]}

Bailly, Christian ^{[1
]}

Corvaia, Nathalie ^{[1
]}

机构：

[1] CIPF, F-74160 St Julien En Genevois, France

来源：

NATURE REVIEWS IMMUNOLOGY | 2010年 / 10卷 / 05期

关键词：

MONOCLONAL-ANTIBODIES; CANCER-THERAPY; COLORECTAL-CANCER; DRUG; GLYCOSYLATION; BINDING; MOUSE; IDENTIFICATION; OPTIMIZATION; SPECIFICITY;

D O I：

10.1038/nri2747

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Antibodies and related products are the fastest growing class of therapeutic agents. By analysing the regulatory approvals of IgG-based biotherapeutic agents in the past 10 years, we can gain insights into the successful strategies used by pharmaceutical companies so far to bring innovative drugs to the market. Many challenges will have to be faced in the next decade to bring more efficient and affordable antibody-based drugs to the clinic. Here, we discuss strategies to select the best therapeutic antigen targets, to optimize the structure of IgG antibodies and to design related or new structures with additional functions.

引用

收藏

页码：345 / 352

页数：8

相关论文

共 71 条

[41] Fully human antibodies from transgenic mouse and phage display platforms [J].

Lonberg, Nils .

CURRENT OPINION IN IMMUNOLOGY, 2008, 20 (04) :450-459

[42] Antibody-based identification of cell surface antigens: targets for cancer therapy [J].

Loo, Deryk T. ;

Mather, Jennie P. .

CURRENT OPINION IN PHARMACOLOGY, 2008, 8 (05) :627-631

[43] PHAGE ANTIBODIES - FILAMENTOUS PHAGE DISPLAYING ANTIBODY VARIABLE DOMAINS [J].

MCCAFFERTY, J ;

GRIFFITHS, AD ;

WINTER, G ;

CHISWELL, DJ .

NATURE, 1990, 348 (6301) :552-554

[44] CHIMERIC HUMAN-ANTIBODY MOLECULES - MOUSE ANTIGEN-BINDING DOMAINS WITH HUMAN CONSTANT REGION DOMAINS [J].

MORRISON, SL ;

JOHNSON, MJ ;

HERZENBERG, LA ;

OI, VT .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1984, 81 (21) :6851-6855

[45] Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities [J].

Natsume, Akito ;

In, Mika ;

Takamura, Hiroyuki ;

Nakagawa, Tomoaki ;

Shimizu, Yukiko ;

Kitajima, Kazuko ;

Wakitani, Masako ;

Ohta, So ;

Satoh, Mitsuo ;

Shitara, Kenya ;

Niwa, Rinpei .

CANCER RESEARCH, 2008, 68 (10) :3863-3872

[46] Development trends for therapeutic antibody fragments [J].

Nelson, Aaron L. ;

Reichert, Janice M. .

NATURE BIOTECHNOLOGY, 2009, 27 (04) :331-337

[47]

OFLAZOGLU E, 2010, MABS, V2, P1

[48] Structural characterization of a human Fc fragment engineered for extended serum half-life [J].

Oganesyan, Vaheh ;

Damschroder, Melissa M. ;

Woods, Robert M. ;

Cook, Kimberly E. ;

Wu, Herren ;

Dall'Acqua, William F. .

MOLECULAR IMMUNOLOGY, 2009, 46 (8-9) :1750-1755

[49] Sym004: A Novel Synergistic Anti-Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy [J].

Pedersen, Mikkel Wandahl ;

Jacobsen, Helle Jane ;

Koefoed, Klaus ;

Hey, Adam ;

Pyke, Charles ;

Haurum, John Sorensen ;

Kragh, Michael .

CANCER RESEARCH, 2010, 70 (02) :588-597

[50] Toward an Effective Targeted Chemotherapy for Multiple Myeloma [J].

Poison, Andrew G. ;

Sliwkowski, Mark X. .

CLINICAL CANCER RESEARCH, 2009, 15 (12) :3906-3907

← 1 2 3 4 5 6 7 8 →